ASCO shared a post on X:
“CYMI: 1/2 of men who’ve undergone prostatectomy for Prostate Cancer will have a rising PSA, which means physicians must locate the biochemical recurrence to tailor treatment.
Nicholas Zaorsky, Amar Kishan and Daniel E Spratt discuss for ASCO DailyNews.”
Further Reading:
FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer